Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
BOCA RATON, Fla., Feb. 08, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S....
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla., Feb. 06, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly...
Sensus Healthcare Announces Retirement of Director Samuel O’Rear
BOCA RATON, Fla., Feb. 01, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel...
Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
BOCA RATON, Fla. , Jan. 30, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on...
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
Ships more than 60 SRT units in 2023To report full financial results and hold conference call on February 8th BOCA RATON, Fla. , Jan. 23, 2024 -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive,...